Lipidor announces positive outcome of feasibility study for development of topical medical cannabis products based on the company's AKVANO technologyPosted by On


STOCKHOLM, Sept. 30, 2020 /PRNewswire/ — Lipidor AB (Nasdaq First North:LIPI) today announces a positive outcome of the feasibility study into the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The study was conducted in collaboration with Cannassure Therapeutics Ltd. , an Israeli company specializing in the development and manufacture of innovative medicinal cannabis products. Under the joint development agreement signed in December 2019, Cannassure has now announced that it intends to exercise its option and begin the negotiation of an exclusive licensing agreement for the use of AKVANO®, Lipidor’s proprietary drug delivery technology, for the indications chosen by Cannassure. The main guidelines for the licencing agreement, including royalties (double digit) to be paid to Lipidor on product sales, were defined in the collaboration agreement.

The collaboration began with an evaluation of the possibility of…

Original Author Link click here to read complete story..

News

AKVANOAnnouncesbasedcannabisCompany039sDevelopmentFeasibilityLipidormedicaloutcomepositiveproductsstudytechnologyTopical

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.